Roche Follow-On Development Strategy Highlighted By Strong 1H Results
This article was originally published in The Pink Sheet Daily
Top oncology specialist Roche’s second quarter saw robust sales growth with new breast cancer medicines Perjeta and Kadcyla selling well, highlighting and further validating its strategy to develop follow-on drugs to replace or renew older treatments while expanding into new disease areas.
You may also be interested in...
The September advisory committee review of Roche’s sBLA for Perjeta will be the first test of the agency’s guidance on using accelerated approval for neoadjuvant breast cancer.
China remains the star in emerging markets, with Roche reporting 26% growth in China for pharma and 19% in diagnostics, and Eli Lilly & Co. reporting 18% growth in China. Bristol-Myers Squibb Co. had little to report on EMs, but it signed a manufacturing agreement with South Korea’s Samsung BioLogics for an undisclosed cancer drug.
Development of dual PPAR agonist aleglitazar terminated due to fractures, renal impairment and heart failure reported in the AleCardio study, leaving another hole in Roche’s cardiovascular/metabolic pipeline.